Beta-Blockers in the Management of Hypertension And/or Chronic Kidney Disease

Overview

Journal Int J Hypertens

Publisher Wiley

Date 2014 Mar 28

PMID 24672712

Citations 15

Authors

Hirofumi Tomiyama

Akira Yamashina

Affiliations

Soon will be listed here.

Abstract

This minireview provides current summaries of beta-blocker use in the management of hypertension and/or chronic kidney disease. Accumulated evidence suggests that atenolol is not sufficiently effective as a primary tool to treat hypertension. The less-than-adequate effect of beta-blockers in lowering the blood pressure and on vascular protection, and the unfavorable effects of these drugs, as compared to other antihypertensive agents, on the metabolic profile have been pointed out. On the other hand, in patients with chronic kidney disease, renin-angiotensin system blockers are the drugs of first choice for achieving the goal of renal protection. Recent studies have reported that vasodilatory beta-blockers have adequate antihypertensive efficacy and less harmful effects on the metabolic profile, and also exert beneficial effects on endothelial function and renal protection. However, there is still not sufficient evidence on the beneficial effects of the new beta-blockers.

Citing Articles

β-blockers and metabolic modulation: unraveling the complex interplay with glucose metabolism, inflammation and oxidative stress.

Drygala S, Radzikowski M, Maciejczyk M Front Pharmacol. 2025; 15:1489657.

PMID: 39759452 PMC: 11695285. DOI: 10.3389/fphar.2024.1489657.

Autonomic modulation with mindfulness-based stress reduction in chronic kidney disease: a randomized controlled trial.

Jeong J, Hu Y, Zanuzzi M, DaCosta D, Sabino-Carvalho J, Li S J Physiol. 2024; 603(2):489-505.

PMID: 39693497 PMC: 11747809. DOI: 10.1113/JP287321.

Autonomic Modulation with Mindfulness-Based Stress Reduction in Chronic Kidney Disease: A Randomized Controlled Trial.

Jeong J, Hu Y, Zanuzzi M, DaCosta D, Li S, Park J medRxiv. 2024; .

PMID: 38699306 PMC: 11065017. DOI: 10.1101/2024.04.17.24306000.

Pattern, frequency and factors associated with inappropriate high dosing in chronic kidney disease patients at a tertiary care hospital in Pakistan.

Hayat M, Ahmad N, Khan S, Mohkumuddin S, Siddique W, Khan A BMC Nephrol. 2023; 24(1):118.

PMID: 37127612 PMC: 10150458. DOI: 10.1186/s12882-023-03167-5.

Reno protective role of amlodipine in patients with hypertensive chronic kidney disease.

Abraham G, Almeida A, Gaurav K, Khan M, Patted U, Kumaresan M World J Nephrol. 2022; 11(3):86-95.

PMID: 35733653 PMC: 9160710. DOI: 10.5527/wjn.v11.i3.86.

References

Ritz E, Rump L . Do beta-blockers combined with RAS inhibitors make sense after all to protect against renal injury?. Curr Hypertens Rep. 2008; 9(5):409-14. DOI: 10.1007/s11906-007-0075-6. View

Neutel J, Schnaper H, Cheung D, Graettinger W, Weber M . Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J. 1990; 120(1):166-71. DOI: 10.1016/0002-8703(90)90174-v. View

Wright R, Reeder G, Herzog C, Albright R, Williams B, Dvorak D . Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002; 137(7):563-70. DOI: 10.7326/0003-4819-137-7-200210010-00007. View

Bakris G, Fonseca V, Katholi R, McGill J, Messerli F, Phillips R . Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004; 292(18):2227-36. DOI: 10.1001/jama.292.18.2227. View

Webb A, Fischer U, Mehta Z, Rothwell P . Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010; 375(9718):906-15. DOI: 10.1016/S0140-6736(10)60235-8. View

Jouven X, Empana J, Schwartz P, Desnos M, Courbon D, Ducimetiere P . Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005; 352(19):1951-8. DOI: 10.1056/NEJMoa043012. View

Neutel J, Smith D, Ram C, Kaplan N, Papademetriou V, Fagan T . Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med. 1993; 94(2):181-7. DOI: 10.1016/0002-9343(93)90181-n. View

Rothwell P, Howard S, Dolan E, OBrien E, Dobson J, Dahlof B . Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010; 9(5):469-80. DOI: 10.1016/S1474-4422(10)70066-1. View

Gapon L, Prilepova A, Tsygolnik M . [Effect of nebivolol on parameters of cerebral haemodynamics and 24-hour blood pressure profile in patients with arterial hypertension]. Kardiologiia. 2005; 45(10):18-22. View

10.

Sarafidis P, Bogojevic Z, Basta E, Kirstner E, Bakris G . Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008; 10(2):112-8. PMC: 8109968. DOI: 10.1111/j.1751-7176.2008.08021.x. View

11.

Messerli F, Bangalore S, Julius S . Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008; 117(20):2706-15. DOI: 10.1161/CIRCULATIONAHA.107.695007. View

12.

Bakris G, Weir M, Secic M, Campbell B, Weis-McNulty A . Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004; 65(6):1991-2002. DOI: 10.1111/j.1523-1755.2004.00620.x. View

13.

Lindholm L, Carlberg B, Samuelsson O . Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005; 366(9496):1545-53. DOI: 10.1016/S0140-6736(05)67573-3. View

14.

Elliott W, Childers W . Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities?. Curr Cardiol Rep. 2011; 13(6):507-16. DOI: 10.1007/s11886-011-0216-z. View

15.

Kohro T, Hayashi D, Yamazaki T, Nagai R . Beta-blocker prescription among Japanese cardiologists and its effect on various outcomes. Circ J. 2010; 74(5):962-9. DOI: 10.1253/circj.cj-09-0613. View

16.

De Caterina A, Leone A . The role of Beta-blockers as first-line therapy in hypertension. Curr Atheroscler Rep. 2011; 13(2):147-53. DOI: 10.1007/s11883-010-0157-9. View

17.

Rinfret S, Abrahamowicz M, Tu J, Humphries K, Eisenberg M, Richard H . A population-based analysis of the class effect of beta-blockers after myocardial infarction. Am Heart J. 2007; 153(2):224-30. DOI: 10.1016/j.ahj.2006.11.008. View

18.

Dhakam Z, Mceniery C, Yasmin , Cockcroft J, Brown M, Wilkinson I . Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens. 2006; 19(2):214-9. DOI: 10.1016/j.amjhyper.2005.08.007. View

19.

Fassbinder W, Quarder O, Waltz A . Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study. Int J Clin Pract. 2000; 53(7):519-22. View

20.

Tangri N, Shastri S, Tighiouart H, Beck G, Cheung A, Eknoyan G . β-Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study. Am J Kidney Dis. 2011; 58(6):939-45. DOI: 10.1053/j.ajkd.2011.06.024. View